Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02741570




Registration number
NCT02741570
Ethics application status
Date submitted
13/04/2016
Date registered
18/04/2016
Date last updated
21/09/2023

Titles & IDs
Public title
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Scientific title
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Secondary ID [1] 0 0
2016-000725-39
Secondary ID [2] 0 0
CA209-651
Universal Trial Number (UTN)
Trial acronym
CheckMate 651
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Head and Neck Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Head and neck

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Nivolumab and Ipilimumab - Specified dose on specified days

Active comparator: Extreme Regimen - Specified dose on specified days
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) =20
Timepoint [1] 0 0
From randomization to date of death or date the participant was last known to be alive (Up to approximately 55 months)
Primary outcome [2] 0 0
Overall Survival (OS) in All Randomized Participants
Timepoint [2] 0 0
From randomization to date of death or date the participant was last known to be alive (Up to approximately 55 months)
Secondary outcome [1] 0 0
Overall Survival (OS) in Randomized Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) = 1
Timepoint [1] 0 0
From randomization to date of death or date the participant was last known to be alive (Up to approximately 65 months)
Secondary outcome [2] 0 0
Progression Free Survival (PFS)
Timepoint [2] 0 0
From randomization to disease progression or death (Up to approximately 65 months)
Secondary outcome [3] 0 0
Objective Response Rate (ORR)
Timepoint [3] 0 0
From randomization up to approximately 65 months
Secondary outcome [4] 0 0
Duration of Objective Response (DOR)
Timepoint [4] 0 0
From randomization to the first documented response (CR or PR) and progression (up to approximately 65 months)

Eligibility
Key inclusion criteria
* Histologically confirmed metastatic or recurrent squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx & larynx) that is not amenable to curative therapy.
* No prior systemic cancer therapy for recurrent or metastatic disease (except if chemotherapy was part of multimodal treatment completed 6 months prior to enrolment).
* Measurable disease detected by imaging exam (CT or MRI).
* Have tumor tissue for PD L1 expression testing, and for oropharyngeal cancer have results from testing of HPV p16 status.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Metastatic or recurrent carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary, squamous cell carcinoma originating from skin and salivary glands or non squamous histologies (eg. mucosal melanoma).
* No prior treatment with anti PD1, anti PD L1, anti CTLA 4 antibody or any other antibody or drugs targeting T cell costimulation or checkpoint pathways, or cetuximab or EGFR inhibitors in any treatment setting.
* Participants with certain diseases such as active autoimmune disease, type I diabetes, hypothyroidism that needs hormone replacement, active infection, psychiatric disorder.
* Inadequate hematologic, renal or hepatic function.

Other protocol defined inclusion/exclusion criteria could apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/10/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
22/09/2022
Sample size
Target
Accrual to date
Final
947
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - 0142 - Blacktown
Recruitment hospital [2] 0 0
Local Institution - 0127 - Darlinghurst
Recruitment hospital [3] 0 0
Local Institution - 0128 - Gosford
Recruitment hospital [4] 0 0
Local Institution - 0019 - St. Leonards
Recruitment hospital [5] 0 0
Local Institution - 0077 - Brisbane
Recruitment hospital [6] 0 0
Local Institution - 0036 - Douglas
Recruitment hospital [7] 0 0
Local Institution - 0021 - Elizabeth Vale
Recruitment hospital [8] 0 0
Local Institution - 0022 - Clayton
Recruitment hospital [9] 0 0
Local Institution - 0131 - Melbourne
Recruitment hospital [10] 0 0
Local Institution - 0020 - Nedlands
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
2250 - Gosford
Recruitment postcode(s) [4] 0 0
2065 - St. Leonards
Recruitment postcode(s) [5] 0 0
4102 - Brisbane
Recruitment postcode(s) [6] 0 0
4814 - Douglas
Recruitment postcode(s) [7] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [8] 0 0
3168 - Clayton
Recruitment postcode(s) [9] 0 0
3000 - Melbourne
Recruitment postcode(s) [10] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Virginia
Country [13] 0 0
United States of America
State/province [13] 0 0
West Virginia
Country [14] 0 0
Austria
State/province [14] 0 0
Linz
Country [15] 0 0
Austria
State/province [15] 0 0
Wien
Country [16] 0 0
Brazil
State/province [16] 0 0
Minas Gerais
Country [17] 0 0
Brazil
State/province [17] 0 0
RIO Grande DO SUL
Country [18] 0 0
Brazil
State/province [18] 0 0
Sao Paulo
Country [19] 0 0
France
State/province [19] 0 0
Somme
Country [20] 0 0
France
State/province [20] 0 0
Bordeaux
Country [21] 0 0
France
State/province [21] 0 0
La Tronche
Country [22] 0 0
France
State/province [22] 0 0
Lille
Country [23] 0 0
France
State/province [23] 0 0
Lyon
Country [24] 0 0
France
State/province [24] 0 0
Marseille
Country [25] 0 0
France
State/province [25] 0 0
Nice Cedex 2
Country [26] 0 0
France
State/province [26] 0 0
Paris
Country [27] 0 0
France
State/province [27] 0 0
Strasbourg
Country [28] 0 0
France
State/province [28] 0 0
Villejuif Cedex
Country [29] 0 0
Germany
State/province [29] 0 0
Bonn
Country [30] 0 0
Germany
State/province [30] 0 0
Freiburg
Country [31] 0 0
Germany
State/province [31] 0 0
Hamburg
Country [32] 0 0
Germany
State/province [32] 0 0
Hannover
Country [33] 0 0
Germany
State/province [33] 0 0
Heidelberg
Country [34] 0 0
Germany
State/province [34] 0 0
Leipzig
Country [35] 0 0
Germany
State/province [35] 0 0
Mainz
Country [36] 0 0
Germany
State/province [36] 0 0
Muenchen
Country [37] 0 0
Germany
State/province [37] 0 0
Ulm
Country [38] 0 0
Germany
State/province [38] 0 0
Wuerzburg
Country [39] 0 0
Greece
State/province [39] 0 0
Athens
Country [40] 0 0
Greece
State/province [40] 0 0
Nea Kifissia
Country [41] 0 0
Greece
State/province [41] 0 0
Thessaloniki
Country [42] 0 0
Ireland
State/province [42] 0 0
Dublin
Country [43] 0 0
Israel
State/province [43] 0 0
Haifa
Country [44] 0 0
Israel
State/province [44] 0 0
Jerusalem
Country [45] 0 0
Israel
State/province [45] 0 0
Petah-tikva
Country [46] 0 0
Israel
State/province [46] 0 0
Ramat-gan
Country [47] 0 0
Israel
State/province [47] 0 0
Tel-Aviv
Country [48] 0 0
Italy
State/province [48] 0 0
MI
Country [49] 0 0
Italy
State/province [49] 0 0
TO
Country [50] 0 0
Italy
State/province [50] 0 0
Cuneo
Country [51] 0 0
Italy
State/province [51] 0 0
Meldola (fc)
Country [52] 0 0
Italy
State/province [52] 0 0
Modena
Country [53] 0 0
Italy
State/province [53] 0 0
Napoli
Country [54] 0 0
Italy
State/province [54] 0 0
Perugia
Country [55] 0 0
Italy
State/province [55] 0 0
Roma
Country [56] 0 0
Japan
State/province [56] 0 0
Aichi
Country [57] 0 0
Japan
State/province [57] 0 0
Chiba
Country [58] 0 0
Japan
State/province [58] 0 0
Fukuoka
Country [59] 0 0
Japan
State/province [59] 0 0
Hokkaido
Country [60] 0 0
Japan
State/province [60] 0 0
Hyogo
Country [61] 0 0
Japan
State/province [61] 0 0
Kanagawa
Country [62] 0 0
Japan
State/province [62] 0 0
Miyagi
Country [63] 0 0
Japan
State/province [63] 0 0
Osaka
Country [64] 0 0
Japan
State/province [64] 0 0
Saitama
Country [65] 0 0
Japan
State/province [65] 0 0
Shizuoka
Country [66] 0 0
Japan
State/province [66] 0 0
Tochigi
Country [67] 0 0
Japan
State/province [67] 0 0
Tokyo
Country [68] 0 0
Japan
State/province [68] 0 0
Kita-gun
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Gangnam-gu
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Seoul
Country [71] 0 0
Mexico
State/province [71] 0 0
Distrito Federal
Country [72] 0 0
Mexico
State/province [72] 0 0
Guanajuato
Country [73] 0 0
Mexico
State/province [73] 0 0
Michoacan
Country [74] 0 0
Mexico
State/province [74] 0 0
Nuevo LEON
Country [75] 0 0
Mexico
State/province [75] 0 0
Oaxaca
Country [76] 0 0
Poland
State/province [76] 0 0
Bydgoszcz
Country [77] 0 0
Poland
State/province [77] 0 0
Gdansk
Country [78] 0 0
Poland
State/province [78] 0 0
Gliwice
Country [79] 0 0
Poland
State/province [79] 0 0
Krakow
Country [80] 0 0
Poland
State/province [80] 0 0
Warszawa
Country [81] 0 0
Spain
State/province [81] 0 0
Barcelona
Country [82] 0 0
Spain
State/province [82] 0 0
L'Hospitalet Del Llobregat
Country [83] 0 0
Spain
State/province [83] 0 0
Madrid
Country [84] 0 0
Spain
State/province [84] 0 0
Sevilla
Country [85] 0 0
Spain
State/province [85] 0 0
Valencia
Country [86] 0 0
Switzerland
State/province [86] 0 0
Basel
Country [87] 0 0
Switzerland
State/province [87] 0 0
Zuerich
Country [88] 0 0
Taiwan
State/province [88] 0 0
Taichung
Country [89] 0 0
Taiwan
State/province [89] 0 0
Taipei
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Durham
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Greater London
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Greater Manchester
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Hampshire
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Surrey
Country [95] 0 0
United Kingdom
State/province [95] 0 0
West Midlands
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Ono Pharmaceutical Co. Ltd
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
Trial website
https://clinicaltrials.gov/study/NCT02741570
Trial related presentations / publications
Hwang M, Seiwert TY. Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era. Lancet Oncol. 2021 Apr;22(4):413-415. doi: 10.1016/S1470-2045(21)00121-2. Epub 2021 Mar 5. No abstract available. Erratum In: Lancet Oncol. 2021 Apr;22(4):e134. doi: 10.1016/S1470-2045(21)00140-6.
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02741570